The level of expression of peroxiredoxin-2 (PRX-2) correlated with the resistance to radio- or chemotherapy in GBM (Park et al., 2000) and the overexpression of TRX, particularly in the hypoxic region of tumors, contributing to chemotherapy resistance, which was negatively regulated by TRX-interacting protein (TXNIP) (Haas et al., 2018). The gene discussed is PRDX2; the disease is glioblastoma.